The project will utilize Hesperos' human-on-a-chip platforms, which can integrate patient cells from major organs. This will make it possible to assess the reactions of body tissue to new drugs. The aim is to test a substance developed against frontotemporal dementia for its effect on the nerve tissue of patients with neurodegenerative diseases.

Further information:
https://hesperosinc.com/hesperos-announces-collaboration-with-psilera/